ArticleOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2019
Short- and Long-term Opioid Use in Patients with Oral and Oropharynx Cancer.
Article in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Unveiling Prescribing Patterns: A Systematic Review of Chronic Opioid Prescriptions After Head and Neck Cancer Surgeries.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2025Pooled it
- Preexisting Psychiatric Risk Factors and Any and Long-Term Opioid Use in Head and Neck Cancer.JAMA otolaryngology-- head & neck surgery · 2025Article
- Machine learning predicting acute pain and opioid dose in radiation treated oropharyngeal cancer patients.Frontiers in pain research (Lausanne, Switzerland) · 2025Article
- How Racialized Approaches to Opioid Use Disorder and Opioid Misuse Management Hamper Pharmacoequity for Cancer Pain.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Advancing Postoperative Pain Management in Oral Cancer Patients: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Systematic Review of Genetic Polymorphisms Associated with Acute Pain Induced by Radiotherapy for Head and Neck Cancers.Clinical and translational radiation oncology · 2023Review
- Temporal characterization of acute pain and toxicity kinetics during radiation therapy for head and neck cancer. A retrospective study.Oral oncology reports · 2023Article
- Sociodemographic Differences in Patient-Reported Pain and Pain Management of Patients With Head and Neck Cancer in a Community Oncology Setting.JCO oncology practice · 2023Article
- Assessing Impact: Implementing an Opioid Prescription Protocol in Otolaryngology.Journal of patient safety · 2022Article
- Association of a Multimodal Intervention With Decreased Opioid Prescribing After Neck Dissection for Malignant Thyroid Disease With Short Hospital Stay.JAMA otolaryngology-- head & neck surgery · 2022Article
- Sociodemographic and Clinical Predictors of Prescription Opioid Use in a Longitudinal Community-Based Cohort Study of Middle-Aged and Older Adults.Journal of aging and health · 2022Article
- Head and neck cancer survivorship consensus statement from the American Head and Neck Society.Laryngoscope investigative otolaryngology · 2022Review
- Opioid therapy vs. multimodal analgesia in head and neck Cancer (OPTIMAL-HN): study protocol for a randomized clinical trial.BMC palliative care · 2021Article
- Therapeutic Perspectives for the Perioperative Period in Oral Squamous Cell Carcinoma (OSCC).Frontiers in oral health · 2021Article
- Risk of Persistent Opioid Use following Major Surgery in Matched Samples of Patients with and without Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- An Analysis and Comparison of Survival and Functional Outcomes in Oropharyngeal Squamous Cell Carcinoma Patients Treated with Concurrent Chemoradiation Therapy within City of Hope Cancer Center Sites.Journal of clinical medicine · 2020Article
- Patient-level factors associated with chronic opioid use in cancer: a population-based cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Emergency Department Visits for Opioid Overdoses Among Patients With Cancer.Journal of the National Cancer Institute · 2020Article
- National Patterns in Prescription Opioid Use and Misuse Among Cancer Survivors in the United States.JAMA network open · 2020Article
- Predicting Persistent Opioid Use, Abuse, and Toxicity Among Cancer Survivors.Journal of the National Cancer Institute · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveOpioid use and abuse is a national health care crisis, yet opioids remain the cornerstone of pain management in cancer. We sought to determine the risk of acute and chronic opioid use with head and neck squamous cell cancer (HNSCC) treatment. STUDY
designRetrospective population-based study.
settingSurveillance, Epidemiology and End Results (SEER)-Medicare database from 2008 to 2011. SUBJECTS AND
methodsIn total, 976 nondistant metastatic oral cavity and oropharynx patients undergoing cancer-directed treatment enrolled in Medicare were included. Opiate use was the primary end point. Univariate and multivariable logistic analyses were completed to determine risk factors.
resultsOf the patients, 811 (83.1%) received an opioid prescription during the treatment period, and 150 patients (15.4%) had continued opioid prescriptions at 3 months and 68 (7.0%) at 6 months. Opioid use during treatment was associated with prescriptions prior to treatment (odds ratio [OR], 3.28; 95% confidence interval [CI], 2.11-5.12) and was least likely to be associated with radiation treatment alone (OR, 0.35; 95% CI, 0.18-0.68). Risk factors for continued opioid use at both 3 and 6 months included tobacco use (OR, 2.23; 95% CI, 1.05-4.71 and OR, 3.84; 95% CI, 1.44-10.24) and opioids prescribed prior to treatment (OR, 3.84; 95% CI, 2.45-5.91 and OR, 3.56; 95% CI, 1.95-6.50). Oxycodone prescribed as the first opioid was the least likely to lead to ongoing use at 3 and 6 months (OR, 0.33; 95% CI, 0.17-0.62 and OR, 0.26; 95% CI, 0.10-0.67).
conclusionPatients with oral/oropharyngeal cancer are at a very high risk for receiving opioids as part of symptom management during treatment, and a significant portion continues use at 3 and 6 months after treatment completion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.